Clinical Trial Detail

NCT ID NCT02961816
Title Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

Hodgkin's lymphoma

diffuse large B-cell lymphoma

non-Hodgkin lymphoma

Therapies

Pyridoxine

Busulfan + Gemcitabine + Melphalan + Panobinostat

Dexamethasone + Filgrastim + Palifermin + Rituximab

Age Groups: adult child

No variant requirements are available.